Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.
Jana StofilovaMonika KvakovaAnna KamlárováEmília HijováIzabela BertkováZuzana GuľašováPublished in: Biomedicines (2022)
Although there are number of available therapies for ulcerative colitis (UC), many patients are unresponsive to these treatments or experience secondary failure during treatment. Thus, the development of new therapies or alternative strategies with minimal side effects is inevitable. Strategies targeting dysbiosis of gut microbiota have been tested in the management of UC due to the unquestionable role of gut microbiota in the etiology of UC. Advanced molecular analyses of gut microbiomes revealed evident dysbiosis in UC patients, characterized by a reduced biodiversity of commensal microbiota. Administration of conventional probiotic strains is a commonly applied approach in the management of the disease to modify the gut microbiome, improve intestinal barrier integrity and function, and maintain a balanced immune response. However, conventional probiotics do not always provide the expected health benefits to a patient. Their benefits vary significantly, depending on the type and stage of the disease and the strain and dose of the probiotics administered. Their mechanism of action is also strain-dependent. Recently, new candidates for potential next-generation probiotics have been discovered. This could bring to light new approaches in the restoration of microbiome homeostasis and in UC treatment in a targeted manner. The aim of this paper is to provide an updated review on the current options of probiotic-based therapies, highlight the effective conventional probiotic strains, and outline the future possibilities of next-generation probiotic and postbiotic supplementation and fecal microbiota transplantation in the management of UC.
Keyphrases
- end stage renal disease
- ulcerative colitis
- immune response
- ejection fraction
- newly diagnosed
- escherichia coli
- randomized controlled trial
- healthcare
- bacillus subtilis
- peritoneal dialysis
- stem cells
- case report
- risk assessment
- bone marrow
- patient reported outcomes
- drug delivery
- mesenchymal stem cells
- health information
- health promotion